Renal involvement in sarcoidosis: histological patterns and prognosis, an Italian survey.
AKI
Acute onset
GenPhenReSa phenotypes
Giant cells
Hypercalcaemia
Interstitial fibrosis
Interstitial infiltrate
Renal sarcoidosis
Steroids
Subacute onset
sACE
sGIN
Journal
Sarcoidosis, vasculitis, and diffuse lung diseases : official journal of WASOG
ISSN: 2532-179X
Titre abrégé: Sarcoidosis Vasc Diffuse Lung Dis
Pays: Italy
ID NLM: 9610928
Informations de publication
Date de publication:
2021
2021
Historique:
received:
22
03
2021
accepted:
09
09
2021
entrez:
8
11
2021
pubmed:
9
11
2021
medline:
9
11
2021
Statut:
ppublish
Résumé
Granulomatous interstitial nephritis in sarcoidosis (sGIN) is generally clinically silent, but in <1% causes acute kidney injury (AKI). This Italian multicentric retrospective study included 39 sarcoidosis-patients with renal involvement at renal biopsy: 31 sGIN-AKI, 5 with other patterns (No-sGIN-AKI), 3 with nephrotic proteinuria. We investigate the predictive value of clinical features, laboratory, radiological parameters and histological patterns regarding steroid response. Primary endpoint: incident chronic kidney disease (CKD) beyond the 1°follow-up (FU) year; secondary endpoint: response at 1°line steroid therapy; combined endpoint: the association of initial steroid response and outcome at the end of FU. Complete recovery in all 5 No-sGIN-AKI-patients, only in 45% (13/29) sGIN-AKI-patients (p=0.046) (one lost in follow-up, for another not available renal function after steroids). Nobody had not response. Primary endpoint of 22 sGIN-AKI subjects: 65% (13/20) starting with normal renal function developed CKD (2/22 had basal CKD; median FU 77 months, 15-300). Combined endpoint: 29% (6/21) had complete recovery and final normal renal function (one with renal relapse), 48% (10/21) had partial recovery and final CKD (3 with renal relapse, of whom one with basal CKD) (p=0.024). Acute onset and hypercalcaemia were associated to milder AKI and better recovery than subacute onset and patients without hypercalcaemia, women had better endpoints than men. Giant cells, severe interstitial infiltrate and interstitial fibrosis seemed negative predictors in terms of endpoints. sGIN-AKI-patients with no complete recovery at 1°line steroid should be treated with other immunosuppressive to avoid CKD, in particular if males with subacute onset and III stage-not hypercalcaemic AKI.
Sections du résumé
BACKGROUND
BACKGROUND
Granulomatous interstitial nephritis in sarcoidosis (sGIN) is generally clinically silent, but in <1% causes acute kidney injury (AKI).
METHODS
METHODS
This Italian multicentric retrospective study included 39 sarcoidosis-patients with renal involvement at renal biopsy: 31 sGIN-AKI, 5 with other patterns (No-sGIN-AKI), 3 with nephrotic proteinuria. We investigate the predictive value of clinical features, laboratory, radiological parameters and histological patterns regarding steroid response. Primary endpoint: incident chronic kidney disease (CKD) beyond the 1°follow-up (FU) year; secondary endpoint: response at 1°line steroid therapy; combined endpoint: the association of initial steroid response and outcome at the end of FU.
RESULTS
RESULTS
Complete recovery in all 5 No-sGIN-AKI-patients, only in 45% (13/29) sGIN-AKI-patients (p=0.046) (one lost in follow-up, for another not available renal function after steroids). Nobody had not response. Primary endpoint of 22 sGIN-AKI subjects: 65% (13/20) starting with normal renal function developed CKD (2/22 had basal CKD; median FU 77 months, 15-300). Combined endpoint: 29% (6/21) had complete recovery and final normal renal function (one with renal relapse), 48% (10/21) had partial recovery and final CKD (3 with renal relapse, of whom one with basal CKD) (p=0.024). Acute onset and hypercalcaemia were associated to milder AKI and better recovery than subacute onset and patients without hypercalcaemia, women had better endpoints than men. Giant cells, severe interstitial infiltrate and interstitial fibrosis seemed negative predictors in terms of endpoints.
CONCLUSIONS
CONCLUSIONS
sGIN-AKI-patients with no complete recovery at 1°line steroid should be treated with other immunosuppressive to avoid CKD, in particular if males with subacute onset and III stage-not hypercalcaemic AKI.
Identifiants
pubmed: 34744417
doi: 10.36141/svdld.v38i3.11488
pii: SVDLD-38-17
pmc: PMC8552569
doi:
Types de publication
Journal Article
Langues
eng
Pagination
e2021017Informations de copyright
Copyright: © 2021 SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES.
Déclaration de conflit d'intérêts
Special thanks to Jacqueline Rodriguez, who revised the manuscript for English language, and to Claudia Giuliani, for graphic support. We express gratitude to Immunopathology Group of Italian Society of Nephrology and to ACSI Onlus “Amici contro la Sarcoidosi Italia”, the Italian national society of Sarcoidosis patients.Francesco Rastelli and Ivano Baragetti were responsible for the work. Other authors contributed to the data collection and reviewed and revised the manuscript as supervisors.Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article.
Références
Lancet. 2003 Mar 29;361(9363):1111-8
pubmed: 12672326
Am J Kidney Dis. 2009 Jul;54(1):159-64
pubmed: 19185401
Am J Pathol. 1976 Jul;84(1):164-92
pubmed: 937513
Semin Respir Crit Care Med. 2010 Aug;31(4):390-403
pubmed: 20665389
Sarcoidosis Vasc Diffuse Lung Dis. 2015 Jan 05;31(4):306-15
pubmed: 25591142
Expert Rev Clin Immunol. 2019 Apr;15(4):391-405
pubmed: 30632406
PLoS One. 2015 Jun 10;10(6):e0129036
pubmed: 26061083
Endocr Rev. 2016 Oct;37(5):521-547
pubmed: 27588937
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):252-260
pubmed: 32476910
Iran J Allergy Asthma Immunol. 2016 Aug;15(4):334-339
pubmed: 27921415
Curr Opin Pulm Med. 2014 Sep;20(5):488-95
pubmed: 25046429
Kidney Int. 2014 Jan;85(1):49-61
pubmed: 24284513
Clin Biochem Rev. 2016 May;37(2):85-98
pubmed: 28303073
Ann Am Thorac Soc. 2017 Dec;14(Supplement_6):S437-S444
pubmed: 29073361
Medicine (Baltimore). 2017 Jul;96(29):e7595
pubmed: 28723801
Sarcoidosis Vasc Diffuse Lung Dis. 2006 Oct;23(3):201-8
pubmed: 18038919
Clin Exp Nephrol. 2019 Oct;23(10):1202-1210
pubmed: 31240503
PLoS One. 2017 May 5;12(5):e0176859
pubmed: 28475583
Int Urol Nephrol. 2018 Mar;50(3):501-508
pubmed: 29404927
Sarcoidosis Vasc Diffuse Lung Dis. 2005 Dec;22 Suppl 1:S4-8
pubmed: 16457011
Sarcoidosis Vasc Diffuse Lung Dis. 2014 Apr 18;31(1):46-54
pubmed: 24751453
Intern Med. 2019 Mar 1;58(5):679-684
pubmed: 30449791
Eur Respir J. 2018 Jan 25;51(1):
pubmed: 29371378
Am J Ophthalmol. 2018 Oct;194:82-87
pubmed: 30053466
Medicine (Baltimore). 2007 May;86(3):170-180
pubmed: 17505256
Lung. 2016 Feb;194(1):91-5
pubmed: 26563332
Am Rev Respir Dis. 1974 Dec;110(6):774-802
pubmed: 4611293
Clin Biochem. 1987 Jun;20(3):213-9
pubmed: 2820616
Dis Markers. 2019 Mar 3;2019:8565423
pubmed: 30944672
Sarcoidosis Vasc Diffuse Lung Dis. 2013 Aug 01;30(2):113-20
pubmed: 24071882
Sarcoidosis Vasc Diffuse Lung Dis. 2003 Jun;20(2):126-32
pubmed: 12870722
Curr Opin Hematol. 2017 Jan;24(1):59-65
pubmed: 27755127
J Am Soc Nephrol. 2011 Jul;22(7):1327-34
pubmed: 21700831
Nephrol Dial Transplant. 2020 Sep 1;35(9):1638-1641
pubmed: 32437544
Kidney Int. 2017 Jun;91(6):1300-1311
pubmed: 28366227
Am J Kidney Dis. 2006 Nov;48(5):856-70
pubmed: 17060009
N Engl J Med. 2007 Nov 22;357(21):2153-65
pubmed: 18032765
Am Fam Physician. 2005 Mar 15;71(6):1153-62
pubmed: 15791892
Kidney Int. 2007 Sep;72(5):632-7
pubmed: 17568781
PLoS One. 2014 Oct 20;9(10):e110778
pubmed: 25329890
Clin Exp Rheumatol. 2019 Nov-Dec;37(6):1052-1064
pubmed: 31498063
Nephrol Dial Transplant. 2014 Oct;29(10):1841-7
pubmed: 24235078
Int J Surg Pathol. 2006 Jan;14(1):57-63
pubmed: 16501836
Medicine (Baltimore). 2009 Mar;88(2):98-106
pubmed: 19282700
Am J Kidney Dis. 2013 Aug;62(2):236-44
pubmed: 23499049
Medicine (Baltimore). 1952 Feb;31(1):1-132
pubmed: 14899212
Kidney Int. 2006 Jul;70(1):165-9
pubmed: 16688117